Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-08-09
2011-08-09
Li, Q. Janice (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S007600, C514S007700, C514S007800
Reexamination Certificate
active
07994125
ABSTRACT:
The present invention relates to the use of Stem Cell Factor in the protection of multiprogenitor cells and in the prevention of chemotherapy-induced depletion of blood cells.
REFERENCES:
patent: 5620685 (1997-04-01), Nishi et al.
patent: 2004/0092445 (2004-05-01), Heuer et al.
patent: 0 423 980 (1991-04-01), None
patent: 92/00376 (1992-01-01), None
Pietsch et al. Effects of human stem cell factor (c-kit ligand) on proliferation of myeloid leukemia cells: heterogeneity in response and synergy with other hematopoietic growth factors. 1992. Blood. Sep. 1;80(5):1199-1206.
Zeuner et al. Stem cell factor protects erythroid precursor cells from chemotherapeutic agents via up-regulation of BCL-2 family proteins. Blood. Jul. 1, 2003;102(1):87-93. Epub Mar. 13, 2003.
Sattler M, Salgia R.Targeting c-Kit mutations: basic science to novel therapies. 2004. Leuk Res. May;28 Suppl 1:S11-20.
Basser et al. J Clin Oncol 1998;16:1899-1908.
Smith et al. Acta Hematol 2001;105:143-50.
Fanning et al. Gynecol Oncol 2000;79:97-100.
Facon et al. Blood 1999;94:1218-25.
Weaver et al. Blood 1996;88:3323-8.
Tong et al. Blood 1993;82:784-91.
Liebmann et al; “Protection From Lethal Irradiation by the Combination of Stem Cell Factor and Tempol”; Radiation Research, 1994, vol. 137, No. 3, pp. 400-404, XP009018564.
Liebmann et al; “Nitric Oxide Modulation Enhances the In Vivo Protection From Lethal Irradiation by Stem Cell Factor”; Radiation Oncology Investigations, 1995, vol. 2, No. 6, pp. 264-268, XP009018562.
Facon et al; “Stem Cell Factor in Combination With Filgrastim After Chemotherapy Improves Peripheral Blood Progenitor Cell Yield and Reduces Apheresis Requirements in Multiple Myeloma Patients: A Randomized, Controlled Trial”; Blood, Aug. 15, 1999, vol. 94, No. 4, pp. 1218-1225, XP002256691.
The Third European Workshop on Cell Death, Feb. 23-28, 2002, Abstract at Workshop, Zeuner et al; “Stem Cell Factor Upregulates BCL-2 Family Members and Protects Erythroid Precursor Cells From Chemotherapy-Induced Apoptosis”, Instituto di Patologia Generale, Universita' di Catania, Italy and Department of Hematology and Oncology, Instituto Superiore di Sanita', Rome, Italy.
Inteniational Search Report of PCT/IB03/00930, Oct. 6, 2003.
Arcasoy et al. “Erythropoietin and erythropoietin receptor expression in head and neck cancer: Relationship to tumor hypoxia” Clin. Cancer Res. 20:20-27 (2005).
Blaise et al. “Rescue of haemopoiesis by a combination of growth factors including stem-cell factor” The Lancet 356:1325-1326 (2000).
Dagnon et al. “Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas” Clin. Cancer Res. 11:993-999 (2005).
Eramo et al. “Chemotherapy resistance of glioblastoma stem cells” Cell Death and Differ. 13:1238-1241 (2006).
Food and Drug Administration, Center for Biologics Evaluation and Research, 24thMeeting of the Biological Response Modifiers Advisory Committee.
Haseyama et al. “Stem cell factor protects c-kit human primary erythroid cells from apoptosis” Exp. Hematol. 29:833-841 (2001).
Hassan et al. “Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis” Acta Haematol. 95:257-262 (1996).
http://.medsafe.govt.nz/profs/datasheet/s/stemgeninj.htm.
Ikeda et al. “Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells” Blood 78:2962-2968 (1991).
Nishio et al. “Stem cell factor prevents fas-mediated apoptosis of human erythroid precursor cells with Src-family kinase dependency” Exper. Hematol. 29:19-29 (2001).
Pidhorecky et al. “Gastrointestinal stromal tumors: Current diagnosis, biologic behavior, and management” Annals of Surgical Oncol. 7:705-712 (2000).
Pietsch et al. “Expression of the c-Kit receptor and its ligand SCF in non-small-cell lung carcinomas” Int. J. Cancer 75:171-175 (1998).
Singer et al. “Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors” Endocrine-Related Cancer 11:861-869 (2004).
Orazi et al. “In vivo effects of recombinant human stem cell factor treatment: A morphologic and immunohistochemical study of bone marrow biopsies” Am. J. Clin. Pathol. 103:177-184 (1995).
Schwartz et al. “Expression of the C-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance” Leuk. Lymphoma 34:85-94 (1999).
Tong et al. “In vivo administration of recombinant methionyl human stem cell factor expands the number of human marrow hematopoietic stem cells” Blood 82:784-791 (1993).
Went et al. “Prevalence of KIT expression in human tumors” J. Clin. Oncol. 22:4514-4522 (2004).
Zeuner et al. “Stem cell factor protects erythroid precursor cells from chemotherapeutic agents via up-regulation of BCL-2 family proteins” Blood 102:87-93 (2003).
Zeuner et al. “Chemotherapy-Induced thrombocytopenia derives from the selective death of megakaryocyte progenitors and can be rescued by stem cell factor” Cancer Res. 67:4767-4773 (2007).
Crawford et at “A phase I trial of recombinant methionyl human stem cell factor in patients with advanced non-small cell lung carcinoma” Proc. Am. Soc. Clin. Oncol. 12:135, abstract 338 1993.
Demetri et al. “A phase I trial of recombinant methionyl human stem cell factor (SCF) in patients with advanced breast carcinoma pre- and post-chemo-therapy with cyclophosphamide and doxorubicin” Proc. Amer. Soc. Clin. Oncol. 12:142, abstract 367(1993).
Zeuner et al. “Stem cell factor upregulates BCL-2 gamily members and protects erythroid precursor cells from chemotherapy-induced apoptosis” The Third European Workshop on Cell Death, Salobrena, Spain, Abstract, Feb. 23-28 (2002).
Amgen “Product Monograph STEMGEN®” pp. 1-22 (Apr. 2004).
De Maria Ruggero Marchiano
Zeuner Ann Pegna
Browdy and Neimark PLLC
Istituto Superiore Di Sanita
Li Q. Janice
LandOfFree
Stem cell factor for preventing chemotherapy-induced... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stem cell factor for preventing chemotherapy-induced..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stem cell factor for preventing chemotherapy-induced... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2763752